Effect of High‐Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Objective: Weight loss has been identified as a negative prognostic factor in amyotrophic lateral sclerosis, but there is no evidence regarding whether a high‐caloric diet increases survival. Therefore, we sought to evaluate the efficacy of a high‐caloric fatty diet (HCFD) for increasing survival. Methods: A 1:1 randomized, placebo‐controlled, parallel‐group, double‐blinded trial (LIPCAL‐ALS study) was conducted between February 2015 and September 2018. Patients were followed up at 3, 6, 9, 12, 15, and 18 months after randomization. The study was performed at 12 sites of the clinical and scientific network of German motor neuron disease centers (ALS/MND‐NET). Eligible patients were randomly assigned (1:1) to receive either HCFD (405kcal/day, 100% fat) or placebo in addition to riluzole (100mg/day). The primary endpoint was survival time, defined as time to death or time to study cutoff date. Results: Two hundred one patients (80 female, 121 male, age = 62.4 ± 10.8 years) were included. The confirmatory analysis of the primary outcome survival showed a survival probability of 0.39 (95% confidence interval [CI] = 0.27–0.51) in the placebo group and 0.37 (95% CI = 0.25–0.49) in the HCFD group, both after 28 months (point in time of the last event). The hazard ratio was 0.97, 1‐sided 97.5% CI = −∞ to 1.44, p = 0.44. Interpretation: The results provide no evidence for a life‐prolonging effect of HCFD for the whole amyotrophic lateral sclerosis population. However, post hoc analysis revealed a significant survival benefit for the subgroup of fast‐progressing patients. ANN NEUROL 2020;87:206–216
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433 · cited 1×
“Patients with possible, probable (clinically or laboratory-supported), or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria were considered for enrollment into the study.(29) Included patients had a disease duration of >6 months and < 3 years, with disease onset de…”
MethodBrown, R. H., & Al-Chalabi, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1603471 · Cited by 2,125
van Es, M. A., Hardiman, O., Chio, A., Al-Chalabi, A., Pasterkamp, R. J., Veldink, J. H., & van den Berg, L. H. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31287-4 · Cited by 1,298
Abe, K., Aoki, M., Tsuji, S., Itoyama, Y., Sobue, G., Togo, M., Hamada, C., Tanaka, M., Akimoto, M., Nakamura, K., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30115-1 · Cited by 935
The phenotypic variability of amyotrophic lateral sclerosis
Swinnen, B., & Robberecht, W. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.184 · Cited by 603
Dyslipidemia is a protective factor in amyotrophic lateral sclerosis
Dupuis, L., Corcia, P., Fergani, A., Gonzalez De Aguilar, J. L., Bonnefont-Rousselot, D., Bittar, R., Seilhean, D., Hauw, J. J., Lacomblez, L., Loeffler, J. P., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000285080.70324.27 · Cited by 552
Self-citationEnergy metabolism in amyotrophic lateral sclerosis
Dupuis, L., Pradat, P.-F., Ludolph, A. C., & Loeffler, J.-P. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70224-6 · Cited by 537
Self-citationDupuis, L., Oudart, H., René, F., de Aguilar, J.-L. G., & Loeffler, J.-P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402026101 · Cited by 529 · cited 6×
“HCFD was hypothesized to be disease-modifying in ALS, as has been suggested by a pilot clinical trial(26) and by preclinical animal studies.(24) Although the administration of HCFD in addition to riluzole was found to be safe in patients with ALS, there was no difference between placebo and HCFD groups in the primary…”
BackgroundResultInfluentialSelf-citationNutritional status is a prognostic factor for survival in ALS patients
Desport, J. C., Preux, P. M., Truong, T. C., Vallat, J. M., Sautereau, D., & Couratier, P. (1999) · Neurology · doi:10.1212/wnl.53.5.1059 · Cited by 486
Hypermetabolism in ALS patients: an early and persistent phenomenon
Bouteloup, C., Desport, J.-C., Clavelou, P., Guy, N., Derumeaux-Burel, H., Ferrier, A., & Couratier, P. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5100-z · Cited by 344
Paganoni, S., Deng, J., Jaffa, M., Cudkowicz, M. E., & Wills, A. (2011) · Muscle & Nerve · doi:10.1002/mus.22114 · Cited by 293
Marin, B., Desport, J. C., Kajeu, P., Jesus, P., Nicolaud, B., Nicol, M., Preux, P. M., & Couratier, P. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.211474 · Cited by 284
Wills, A.-M., Hubbard, J., Macklin, E. A., Glass, J., Tandan, R., Simpson, E. P., Brooks, B., Gelinas, D., Mitsumoto, H., Mozaffar, T., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60222-1 · Cited by 266
Dorst, J., Kühnlein, P., Hendrich, C., Kassubek, J., Sperfeld, A. D., & Ludolph, A. C. (2011) · Journal of Neurology · doi:10.1007/s00415-010-5805-z · Cited by 263
Self-citationHypermetabolism in ALS: Correlations with Clinical and Paraclinical Parameters
Desport, J.-C., Torny, F., Lacoste, M., Preux, P.-M., & Couratier, P. (2005) · Neurodegenerative Diseases · doi:10.1159/000089626 · Cited by 234
Nutritional assessment and survival in ALS patients
Claude Desport, P. M. P. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/14660820050515386 · Cited by 198
Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis
Gorges, M., Vercruysse, P., Müller, H.-P., Huppertz, H.-J., Rosenbohm, A., Nagel, G., Weydt, P., Petersén, Å., Ludolph, A. C., Kassubek, J., et al. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-315795 · Cited by 171
Self-citationPremorbid body mass index and risk of amyotrophic lateral sclerosis
O'Reilly, É. J., Wang, H., Weisskopf, M. G., Fitzgerald, K. C., Falcone, G., McCullough, M. L., Thun, M., Park, Y., Kolonel, L. N., & Ascherio, A. (2013) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2012.735240 · Cited by 168
Lower serum lipid levels are related to respiratory impairment in patients with ALS
Chiò, A., Calvo, A., Ilardi, A., Cavallo, E., Moglia, C., Mutani, R., Palmo, A., Galletti, R., Marinou, K., Papetti, L., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c1df1e · Cited by 165 · cited 1×
“We also did not find significant differences with regard to secondary outcome parameters, such as function (ALSFRS-R), body weight, and SVC, which had previously been linked with hypercholesterinemia.(35) Therefore, the results do not provide evidence of a disease-modifying effect for HCFD in the whole ALS population…”
ResultPrediagnostic body fat and risk of death from amyotrophic lateral sclerosis: The EPIC cohort
Gallo, V., Wark, P. A., Jenab, M., Pearce, N., Brayne, C., Vermeulen, R., Andersen, P. M., Hallmans, G., Kyrozis, A., Vanacore, N., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840689 · Cited by 155
Dupuis, L., Dengler, R., Heneka, M. T., Meyer, T., Zierz, S., Kassubek, J., Fischer, W., Steiner, F., Lindauer, E., Otto, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037885 · Cited by 151
Self-citationAhmed, R. M., Irish, M., Piguet, O., Halliday, G. M., Ittner, L. M., Farooqi, S., Hodges, J. R., & Kiernan, M. C. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00380-4 · Cited by 130
Dorst, J., Dupuis, L., Petri, S., Kollewe, K., Abdulla, S., Wolf, J., Weber, M., Czell, D., Burkhardt, C., Hanisch, F., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7646-2 · Cited by 128 · cited 1×
“Targeting weight loss in ALS may be therapeutically useful, because increasing energy content of the diet increased survival in ALS mouse models(24) and showed efficacy in humans in a pilot clinical trial in gastrostomized ALS patients(26) as well as in a longitudinal register of percutaneous endoscopic gastrostomy (P…”
BackgroundSelf-citationPeter, R. S., Rosenbohm, A., Dupuis, L., Brehme, T., Kassubek, J., Rothenbacher, D., Nagel, G., & Ludolph, A. C. (2017) · European Journal of Epidemiology · doi:10.1007/s10654-017-0318-z · Cited by 113 · cited 1×
“Epidemiological evidence suggests that ALS patients suffer from catabolism(4) and begin to lose weight > 10 years before the onset of motor symptoms.(5,6) Furthermore, increased risk of ALS is associated with lower body mass index(7,8) as well as with abnormal levels of circulating metabolic hormones.”
BackgroundSelf-citationAlterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis
Vercruysse, P., Sinniger, J., El Oussini, H., Scekic-Zahirovic, J., Dieterlé, S., Dengler, R., Meyer, T., Zierz, S., Kassubek, J., Fischer, W., et al. (2016) · Brain · doi:10.1093/brain/aww004 · Cited by 104
Self-citationCykowski, M. D., Takei, H., Schulz, P. E., Appel, S. H., & Powell, S. Z. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0171-1 · Cited by 104
Adipose Tissue Distribution Predicts Survival in Amyotrophic Lateral Sclerosis
Lindauer, E., Dupuis, L., Müller, H.-P., Neumann, H., Ludolph, A. C., & Kassubek, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067783 · Cited by 100
Self-citationLudolph, A. C., Schuster, J., Dorst, J., Dupuis, L., Dreyhaupt, J., Weishaupt, J. H., Kassubek, J., Weiland, U., Petri, S., Meyer, T., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30176-5 · Cited by 93
Self-citationDorst, J., Cypionka, J., & Ludolph, A. C. (2013) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2013.823999 · Cited by 86 · cited 1×
“It has been shown that high-caloric nutrition can stabilize body weight.(25) Targeting weight loss in ALS may be therapeutically useful, because increasing energy content of the diet increased survival in ALS mouse models(24) and showed efficacy in humans in a pilot clinical trial in gastrostomized ALS patients(26) as…”
BackgroundSelf-citationBody Mass Index and Amyotrophic Lateral Sclerosis: A Study of US Military Veterans
Mariosa, D., Beard, J. D., Umbach, D. M., Bellocco, R., Keller, J., Peters, T. L., Allen, K. D., Ye, W., Sandler, D. P., Schmidt, S., et al. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kww140 · Cited by 67 · cited 1×
“Epidemiological evidence suggests that ALS patients suffer from catabolism(4) and begin to lose weight > 10 years before the onset of motor symptoms.(5,6) Furthermore, increased risk of ALS is associated with lower body mass index(7,8) as well as with abnormal levels of circulating metabolic hormones.”
BackgroundNagel, G., Peter, R. S., Rosenbohm, A., Koenig, W., Dupuis, L., Rothenbacher, D., & Ludolph, A. C. (2017) · Scientific Reports · doi:10.1038/s41598-017-04706-5 · Cited by 52 · cited 1×
“Furthermore, increased risk of ALS is associated with lower body mass index(7,8) as well as with abnormal levels of circulating metabolic hormones.(9,10) Moreover, weight loss and metabolic status indirectly assessed by circulating lipids(15) or body fat distribution(16) are strong predictors of survival.”
BackgroundSelf-citationRosenbohm, A., Nagel, G., Peter, R. S., Brehme, T., Köenig, W., Dupuis, L., Rothenbacher, D., Ludolph, A. C., & for the ALS Registry Study Group (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.5129 · Cited by 38
Self-citationNakamura, M., Bieniek, K. F., Lin, W.-L., Graff‐Radford, N. R., Murray, M. E., Castanedes‐Casey, M., Desaro, P., Baker, M., Rutherford, N. J., Robertson, J., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1431-2 · Cited by 31
Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: The EPIC cohort
Gallo, V., Wark, P., Jenab, M., Pearce, N. E., Brayne, C., Vermeulen, R. C. H., Andersen, P., Hallmans, G., Kyrozis, A., Vanacore, N., et al. (2013) · Rivm Repository (Netherlands National Institute for Public Health and the Environment) · Cited by 18
Cited by
Feldman, E. L., Goutman, S. A., Petri, S., Mazzini, L., Savelieff, M. G., Shaw, P. J., & Sobue, G. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01272-7 · Cited by 1,129
Self-citationTrial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Miller, T. M., Cudkowicz, M. E., Genge, A., Shaw, P. J., Sobue, G., Bucelli, R. C., Chiò, A., Van Damme, P., Ludolph, A. C., Glass, J. D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204705 · Cited by 966
Self-citationJanse van Mantgem, M. R., van Eijk, R. P. A., van der Burgh, H. K., Tan, H. H. G., Westeneng, H.-J., van Es, M. A., Veldink, J. H., & van den Berg, L. H. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-322909 · Cited by 98
Michels, S., Kurz, D., Rosenbohm, A., Peter, R. S., Just, S., Bäzner, H., Börtlein, A., Dettmers, C., Gold, H.-J., Kohler, A., et al. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11630-4 · Cited by 35
“Consistently, beneficial effects have been reported for interventions with high-fat nutritional supplements, including prolonged survival in fast progressing patients, decreased decline of motor function, stabilization of body weight, and reduction of serum neurofilament light chain levels [8, 9, 54].”
BackgroundSelf-citationJanse van Mantgem, M. R., van Rheenen, W., Hackeng, A. V., van Es, M. A., Veldink, J. H., van den Berg, L. H., & van Eijk, R. P. A. (2023) · Neurology · doi:10.1212/wnl.0000000000201657 · Cited by 28
“Elucidating the interplay between clinical phenotype and lipid metabolism may reveal potential therapeutic interventions and better address the mixed results from dietary interventions obtained thus far.(15,16) In this study, therefore, we aim to summarize the current literature and to explore the relationships betwee…”
BackgroundMethod
Metadata
- Authors
- Ludolph, A. C., Dorst, J., Dreyhaupt, J., Weishaupt, J. H., Kassubek, J., Weiland, U., Meyer, T., Petri, S., Hermann, A., Emmer, A., Grosskreutz, J., Grehl, T., Zeller, D., Boentert, M., Schrank, B., Prudlo, J., Winkler, A. S., Gorbulev, S., Roselli, F., Schuster, J., Dupuis, L., & for the LIPCAL‐ALS Study Group
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2020-01-06
- Volume
- 87
- Issue
- 2
- Pages
- 206-216
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2996023104
- Cited by
- 169
- References
- 34
- FWCI
- 10.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.